Will Thermo Fisher's (TMO) New EXENT Myeloma Platform and Q2 Results Shift Its Diagnostics Narrative?

Thermo Fisher Scientific recently announced strong Q2 2026 results with US$11.99 billion in sales and US$1.74 billion in net income, alongside new diagnostic product launches and FDA clearances, including the EXENT multiple myeloma platform. While these developments reinforce the company's innovation narrative and could deepen its role in clinical workflows, ongoing risks like China exposure and margin pressure in Analytical Instruments persist. The new EXENT platform could support optimistic revenue and earnings forecasts, but investors should weigh these gains against market uncertainties and explore various fair value estimates.